FLT3 and acute myeloid leukemia: The current standard of care for eligible patients with FLT3-mutant AML is frontline midostaurin in combination with intensive chemotherapy and consideration for allogeneic haematopoietic stem cell transplant (alloHSCT) in first remission, given the high relapse rates after traditional cytotoxic chemotherapy.